To investigate the clinical efficacy of modified-Hulubawan on early diabetic kidney disease(DN) with deficiency of kidney yang,and to explore whether its mechanism is related to improving oxidative stress.Methods:A total of 30 cases of patients diagnosed as stage Ⅲ diabetic kidney disease with deficiency of kidney yang who were admitted to Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology from June 2016 to August 2019 were selected as research objects.They were divided into the control group and modified-Hulubawan treatment group according to the random number table method,15 cases in each group.The treatment group was given additionally oral modified-Hulubawan on the basis of conventional treatment,and the control group have no special intervention besides basic treatment.All the cases were treated for 12 weeks.The blood glucose,blood lipids,liver and kidney functions,clinical effect and plasma antioxidant indexes were compared between the two groups.Results:The total effective rate of modified-Hulubawan treatment group was 85%,which was significantly higher than that of control group(20%),and the difference was statistically significant(P<0.05).Before treatment,there was no statistical significance in the comparison of fasting blood glucose and glycosylated hemoglobin between the two groups(P>0.05),there were also no statistically significant differences in serum lipid,liver and kidney function and urinary albumin excretory rate(UAER) between the two groups(P>0.05).There was no statistically significant difference between superoxide dismutase(SOD) and malondialdehyde(MDA) before treatment(P>0.05).After 12 weeks of treatment,there were no statistically significant differences in FBG,HbA1c,blood lipid,liver and kidney function between the two groups(P>0.05).The urinary albumin excretion rate of the treatment group was significantly lower than that of the control group(P<0.05).The plasma MOD level of treatment group was lower than that of control group(P<0.05),and the plasma SOD level was much higher than that of control group(P<0.05).No adverse events occurred during the follow-up.Conclusion:Modified-hulubawan showed significant efficacy on early diabetic kidney disease and it could sharply reduce urinary albumin excretory rate and it had high safety.The mechanism might be related to improving oxidative stress of diabetic kidney disease.